期刊
JOURNAL OF NEUROLOGY
卷 263, 期 8, 页码 1473-1494出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-016-8045-z
关键词
Myasthenia gravis; Pathogenesis; Treatment guidelines
资金
- Fresenius Medical Care
- Genzyme
- Novartis
- Roche
- Bayer Schering
- Biogen Idec Genzyme
- Merck Serono
- TEVA
- Bayer/Schering
- Biogen Idec
- Sanofi-Genzyme
- Medical Park AG
- Bayer Vital
- MSD
- Bayer Schering Pharma
- Biogen Idec/Elan Corporation
Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission. The clinical hallmark of MG consists of fluctuating fatigability and weakness affecting ocular, bulbar and (proximal) limb skeletal muscle groups. MG may either occur as an autoimmune disease with distinct immunogenetic characteristics or as a paraneoplastic syndrome associated with tumors of the thymus. Impairment of central thymic and peripheral self-tolerance mechanisms in both cases is thought to favor an autoimmune CD4(+) T cell-mediated B cell activation and synthesis of pathogenic high-affinity autoantibodies of either the IgG1 and 3 or IgG4 subclass. These autoantibodies bind to the nicotinic acetylcholine receptor (AchR) itself, or muscle-specific tyrosine-kinase (MuSK), lipoprotein receptor-related protein 4 (LRP4) and agrin involved in clustering of AchRs within the postsynaptic membrane and structural maintenance of the neuromuscular synapse. This results in disturbance of neuromuscular transmission and thus clinical manifestation of the disease. Emphasizing evidence from clinical trials, we provide an updated overview on immunopathogenesis, and derived current and future treatment strategies for MG divided into: (a) symptomatic treatments facilitating neuromuscular transmission, (b) antibody-depleting treatments, and (c) immunotherapeutic treatment strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据